Highest-materiality recent filing
ORIC initiates Himalayas-1 Phase 3 trial for rinzimetostat; Q2 cash $387.6M, R&D $36.3M
Initiated Himalayas-1 global Phase 3 registrational trial for rinzimetostat in mCRPC; ~600 patients, 25 countries, primary endpoint rPFS.
ORIC shareholders approve amended equity plan, elect two Class III directors at annual meeting
Shareholders approved amended 2020 Equity Incentive Plan (61.2M for, 27.3M against); annual share increase cut from 5% to 4% of outstanding, evergreen cap removed.
ORIC Q1 2026: rinzimetostat RP3D for Phase 3; $419.7M cash; enozertinib data due 2H 2026
Rinzimetostat 400 mg QD + darolutamide data showed landmark rPFS 93%/84%/84% at 3/4/5 months; no Grade 4/5 TRAEs.
ORIC reports Q4 2025 cash of $392.3M; positive Phase 1b data for rinzimetostat and enozertinib
Cash and investments $392.3M at Dec 31, 2025; proforma $412.3M after $20M ATM in 2026; runway into 2H 2028.
ORIC Pharma Q3 2025: $413M cash; ORIC-944 dose exploration complete with positive data
Cash and investments of $413M as of Sep 30, 2025; expected to fund operating plan into 2H 2028.
ORIC Pharma restructures, cuts 20% workforce, and extends cash runway to 2H 2028
Initiated strategic pipeline prioritization, eliminating discovery research and reducing workforce by ~20%; expects ~$1.9M one-time charge in Q3 2025.
ORIC raises $125M; ORIC-944 Phase 1b shows 59% PSA50 response in mCRPC
$125M private placement of 19.2M shares/pre-funded warrants at $6.50/share; led by SR One; close expected May 29, 2025.
ORIC Q1 cash $224M; extends runway to 2027; plans Phase 3 for 2 programs in 2026
Cash and investments $223.8M at March 31, 2025; expected to fund operations into 2027 (vs previous guidance of late 2026).
ORIC updates registrational plans for lead drugs, extends cash runway into 2027
ORIC-944 first Phase 3 trial in mCRPC expected 1H 2026; combination dose escalation data in 1H and 2H 2025.
ORIC Pharma Q4/FY2024: $256M cash; R&D spend $114.1M; seven data readouts anticipated
Cash $256M as of Dec 31, 2024; expected to fund operations into late 2026.
ORIC Pharma Q2 cash $308.5M; ORIC-114 expansion and ORIC-944 combo dosing underway
Cash and investments $308.5M as of June 30, 2024; expected to fund operations into late 2026.
ORIC Pharma reports Q1 2024 cash of $331.5M; advances ORIC-114 and ORIC-944 trials
Cash and investments $331.5M as of March 31, 2024, expected to fund operations into late 2026.
ORIC Pharma Q4 2023: R&D expenses up to $24.5M; cash $235M; pipeline progress on ORIC-944/114
Q4 2023 R&D expenses $24.5M (up $8.2M YoY); G&A $6.9M; cash and investments $235M at Dec 31, 2023.
ORIC raises $125M in private placement; extends cash runway into late 2026
Sold 12.5M shares at $10.00 each; gross proceeds approx. $125M.
As of Nov 28, 2023, 23 patients dosed (400-2400 mg QD); 100% triple-class refractory, 91% penta-refractory.
ORIC-114 Phase 1 data shows first confirmed CNS complete response in EGFR exon 20 NSCLC
81% of EGFR exon 20 NSCLC patients had prior exon 20 targeted agents; 86% had CNS metastases at baseline.
ORIC Q2 2023 cash $273.7M, $85M private placement; clinical data milestones set
Cash and investments $273.7M as of June 30, 2023; expected to fund operating plan into late 2025.
ORIC raises $85M in private placement led by Nextech at $7.00/share
Gross proceeds ~$85M from sale of ~12.1M shares/pre-funded warrants at $7.00/share (15% premium to 30-day VWAP).
ORIC reports Q1 cash $208.9M; three Phase 1b data readouts expected H2 2023
Cash and investments $208.9M as of March 31, 2023; funds operations into H1 2025.
ORIC Pharma partners with Pfizer on ORIC-533 Phase 2 combo study; Pfizer invests $25M
Pfizer to invest $25M for 5,376,344 shares at $4.65/share in registered direct offering.
ORIC discontinues ORIC-101 after Phase 1b failures; cash runway extended to 2H 2024
ORIC-101 discontinued after interim Phase 1b analyses showed insufficient activity; median PFS 3.7 months in prostate, 1.9 months in pancreatic cohorts.
ORIC Pharma reports $280.8M cash; pipeline milestones extend into 2023
Cash, cash equivalents and investments of $280.8M as of Dec 31, 2021; funds operations into first half of 2024.
Cash, cash equivalents and investments of $296.5 million, expected to fund operations into 2024.
ORIC presents Phase 1b data on ORIC-101 in prostate cancer and preclinical data on ORIC-114
ORIC-101 (240 mg) + enzalutamide well tolerated at RP2D; adverse events mostly Grade 1-2, consistent with enzalutamide alone.
On November 9, 2021, Carl Gordon, Ph.D., C.F.A. submitted his resignation as a director of ORIC Pharmaceuticals, Inc.
On November 9, 2021, the Board appointed Angie You, Ph.D. to serve as a Class II director, with a term expiring at the Company’s 2022 annual meeting of stockholders, as well as serve as a member of the Company’s Audit Committee and Nominating and Corporate Governance Committee.
Max materiality 0.85 · Median 0.55 · Most common event other_material